Ccrf cem

Metastatic human pancreatic cancer cells, L3.6pl, were obtained from Dr. Jose Trevino (Department of Surgery, University of Florida or UF) while human breast adenocarcinoma cells, MCF7, were provided by Dr. Carlos Rinaldi (Department of Chemical Engineering, UF), which were originally purchased from American Type Culture Collection (ATCC). Acute lymphoblastic leukemia cells CCRF-CEM were purchased from ATCC. The L3.6pl cells and MCF7 cells were cultured in DMEM media (ATCC) supplemented with 10% fetal bovine serum (FBS, GIBCO) and 100 units/mL penicillin–streptomycin (Cellgro, Manassas, VA). The CCRF-CEM cells were cultured in RPMI 1640 media (ATCC) with 10% FBS and 100 units/mL penicillin–streptomycin. All cells were cultured and maintained at 37 °C with 5% CO₂.

CCRF-CEM (human leukaemia) and HeLa (cervical adenocarcinoma) cell lines were purchased from American Type Culture Collection (Manassas, VA). CCRF-CEM cells were cultured in RPMI-1640 medium (American Type Culture Collection), with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and HeLa cells were cultured in Dulbecco's modification of Eagle's medium (Fisher Scientific) with 15% fetal bovine serum and 0.5 mg mL^–1 penicillin–streptomycin (Sigma, St. Louis, MO), both at 37 °C in 5% CO₂ atmosphere. HeLa cells were grown to 80% confluency for 48 h before incubation with probes.

The human T-ALL cell lines Jurkat (E6.1), CCRF-CEM, HSB-2 and Molt-3 were from ATCC (Manassas, VA) and were cultured in RPMI 1640 medium containing 10% of fetal bovine serum, 100 units/ml penicillin and streptomycin, and 2 mmol/l glutamine (complete medium).
T-ALL patients were diagnosed and treated at Hôpital Saint-Louis (Paris, France). The patients or relatives have signed the consent forms according to the Declaration of Helsinki. Hôpital Saint-Louis and Institut Universitaire d’Hématologie Institutional Review Board approved the study. The study was performed with cryopreserved leukemic cells isolated from the blood of three stage IV T-ALL patients at diagnosis.

CCRF-CEM (CCL-119, human T lymphoblastic leukemia cell line) and K-562 (CCL-243, chronic myelogenous leukemia cell line) were purchased from ATCC (Manassas, VA) and maintained in RPMI-1640 supplemented with 10% FBS. NK-92MI (natural killer cell) was purchased from ATCC (Manassas, VA) and maintained in alpha minimum essential medium with recommended supplements. Primary Aortic Smooth Muscle Cells were purchased from ATCC (Manassas, VA) and maintained in M231 containing Smooth Muscle Cell Growth Supplement. Human bone marrow CD34+ hematopoietic stem cells were purchased from StemCell Technologies (Tukwila, WA,) and expanded with StemSpan serum-free expansion medium supplemented with CC100 cytokine supplements. hMSC (normal human bone marrow derived mesenchymal stem cells) was purchased from Lonza (Walkersville, MD) and maintained in recommended growth medium (Lonza). RFP-Tagged human bone marrow derived MSCs (RFP-MSCs) were purchased from Angio-Proteomie (Boston, MA) and maintained in stem cell growth medium (Lonza). Cells were maintained at 37 °C in an atmosphere of 5% CO₂ and 95% relative humidity.

The murine HCC cell line HCA-1 and the human HCC cell line JHH-7 were kindly provided by Dan Duda, Massachusetts General Hospital, Boston, MA. The HCA-1 cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Corning). The JHH-7 cells were cultured in DME/F12 medium (Corning), and CCRF-CEM (T cell acute lymphoblastic leukemia; ATCC) cells were kept in RPMI-1640 medium (Gibco). The culture media were supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin and streptomycin (HyClone). The cells were maintained at 37 °C in an incubator (Thermo Fisher Scientific) with an atmosphere of 5% CO₂. HEK293T cells (ATCC) were kept in DMEM (Gibco).